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Background: In order to determine the clinical usefulness of the MicroScan (Siemens Healthcare Diagnostics, USA) MICroSTREP 
plus antimicrobial panel (MICroSTREP) for testing antimicrobial susceptibility of ß-hemolytic streptococci (BHS) and viridans group 
streptococci (VGS), we compared the accuracy of MICroSTREP with that of the CLSI reference method. 
Methods: Seventy-five BHS and 59 VGS isolates were tested for antimicrobial susceptibility to ampicillin, penicillin, cefotaxime, me-
ropenem, erythromycin, clindamycin, levofloxacin, and vancomycin by using MICroSTREP and the CLSI agar dilution method. 
Results: The overall essential agreement with regard to minimum inhibitory concentrations (MICs) (within ±1 double dilution) be-
tween MICroSTREP and the CLSI reference method was 98.2%, and categorical agreement (CA) was 96.9%. For the BHS isolates, the 
CA for erythromycin was 96.0%, whereas that for cefotaxime, meropenem, levofloxacin, and vancomycin (for ampicillin, penicillin, 
and clindamycin; 98.7%) was 100%. For the VGS isolates, the CA for penicillin was 84.7% and that for erythromycin, clindamycin, 
and vancomycin (for meropenem, 86.5%; for ampicillin, 88.1%; and for cefotaxime and levofloxacin, 96.6%) was 100%. All categori-
cal errors of penicillin and ampicillin in the VGS isolates were minor. 
Conclusions: The accuracy of MICroSTREP is comparable to that of the CLSI reference method, suggesting that this panel can be 
effective for testing antimicrobial susceptibility of BHS and VGS. 
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β-Hemolytic streptococcal isolates obtained from hu-
mans can be subdivided into large-colony and small-colony 
(<0.5 mm in diameter) formers. Large colony formers in-
clude Streptococcus pyogenes (Lancefield group A antigen), 
Streptococcus agalactiae (Lancefield group B antigen), and 
Streptococcus dysgalactiae subsp. equisimilis (Lancefield 
group C and G antigens) [1]. The small-colony-forming 
β-hemolytic strains with Lancefield group A, C, F, or G an-
tigens are considered part of the viridans group streptococci 
(VGS). VGS also include Streptococcus mitis, Streptococcus 
oralis, Streptococcus mutans, Streptococcus salivarius, Strep-
tococcus sanguinis, and Streptococcus bovis [1]. Although 
penicillin remains the drug of choice in the treatment of in-
fections caused by large-colony-forming β-hemolytic strep-
tococci (BHS), drug tolerance and clinical therapeutic fail-
ures have been reported [2]. Macrolides and lincosamides 
have been frequently used to prevent β-lactam allergies in 
patients. These agents are also used in empiric and preven-
tive therapies for the treatment of BHS infections [3, 4]. 
However, recent studies have shown considerable changes 
in the susceptibility of BHS to erythromycin and clindamy-
cin, although different resistance rates to these agents owing 
to geographical variation and investigators have been re-
ported [5-7]. β-Lactam agents have been the treatment of 
choice for VGS infections; however, increase in the inci-
dence of VGS with multidrug-resistance to penicillin and 
other agents, such as cephalosporins, macrolides, lincos-
amides, tetracycline, quinupristin-dalfopristin, and quino-
lones, has been reported [7, 8]. Moreover, CLSI has recom-
mended that VGS isolated from normally sterile body sites 
should be tested for penicillin susceptibility by using a min-186     www.kjlm.org
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imum inhibitory concentration (MIC) method and inter-
pretive criteria [9]. Accurate susceptibility testing for BHS 
and VGS is required in order to guide appropriate antimi-
crobial therapy and to monitor further spread of resistant 
pathogens. Rising drug resistance of BHS and VGS has in-
creased the need for accurate determination of antimicro-
bial susceptibility in a timely manner in clinical microbiol-
ogy laboratories. Rapid reporting of the results of an anti-
microbial susceptibility test (AST) has been shown to im-
prove patient outcomes and reduce hospital costs [10, 11]. 
Because there are significant differences in the susceptibility 
of BHS and VGS to β-lactam agents, there are separate in-
terpretive criteria for the susceptibility of the 2 groups of or-
ganisms to ampicillin, penicillin, cefotaxime, ceftriaxone, 
and cefepime [9]. 
Automated commercial susceptibility test systems for 
streptococci offer reliable AST results for MIC measurement 
and help accurately determine the antimicrobial susceptibil-
ity profile according to the Streptococcus group. However, 
most studies are focused on evaluating the AST performan-
ce of Streptococcus pneumoniae. To the best of our knowl-
edge, no study has been conducted to evaluate the accuracy 
of the automated MicroScan (Siemens Healthcare Diagnos-
tics, Sacramento, CA, USA) AST system for susceptibility 
testing of BHS and VGS. Therefore, this study was designed 
to evaluate the clinical usefulness of the MicroScan MI-
CroSTREP plus antimicrobial panel (MICroSTREP) as a 
susceptibility testing system for BHS and VGS. 
MATERIALS AND METHODS
1. Bacterial isolates 
A total of 134 isolates of BHS (75 isolates) and VGS (59 
isolates) were stocked from various clinical specimens ob-
tained from January to December 2009 at Wonju Christian 
Hospital, Korea. Multiple isolates from the same patient 
were avoided. The predominant specimen sources were 
wounds (60, 44.8%), urinary tract (27, 20.1%), blood (13, 
9.7%), and respiratory tract (11, 8.2%). The isolates were 
identified by on the basis of hemolytic patterns on 5% sheep 
blood agar, colony morphology, Gram staining, catalase re-
action, and findings obtained by using the VITEK-2 GP 
identification system (bioMérieux, Marcy l’Étoile, France). 
The strains were stored in thioglycolate broth containing 
20% glycerol at -70˚C until analysis. Thereafter, the frozen 
isolates were thawed, inoculated onto a 5% sheep blood 
agar plate, and incubated at 35˚C overnight. Pure isolates 
from 3 consecutive subcultures were tested for susceptibil-
ity. All 134 strains were tested using MICroSTREP and the 
CLSI reference method. Of the 134 isolates, BHS were S. 
agalactiae (61 isolates), S. pyogenes (9), and S. dysgalactiae 
(5), and VGS were S. mitis (34), Streptococcus anginosus (18), 
S. salivarius (3), S. sanguinis (2), and S. mutans (2). 
2. Reference method
Susceptibility to penicillin, ampicillin, cefotaxime, eryth-
romycin, clindamycin, levofloxacin (Sigma Chemical Co, 
St. Louis, MO, USA), meropenem (Yuhan, Seoul, Korea), 
and vancomycin (Daewoong Lilly, Seoul, Korea) was tested 
using the agar dilution method according to the recom-
mendations of the CLSI [9]. Mueller-Hinton agar with 5% 
defibrinated sheep blood was used for the agar dilution test. 
Inocula were prepared by suspending colonies in tryptic 
soy broth to obtain approximately 10
4 colonies on inocula-
tion using a Steers replicator (Craft Machine Inc, Chester, 
PA, USA). MIC was determined after 24 hr of incubation at 
35˚C. S. pneumoniae (ATCC 49619) was used as a control 
in the MIC determination. MIC was defined as the lowest 
concentration of an agent that yielded no growth or a mark-
ed change in the appearance of the growth plate as compared 
to the growth control plate. The AST results obtained for the 
reference strains were consistently within the acceptable 
MIC range. 
3. MicroScan MICroSTREP test 
In the MicroScan MICroSTREP system, Renok hydrator/
inoculator was used to deliver 115 µL of Mueller-Hinton 
broth with 3% lysed horse blood to each well. After inocula-
tion with a 0.5 McFarland standard bacterial suspension, 
the panels were incubated at 35˚C in ambient air for 20-24 
hr and read using the MicroScan WalkAway System (Sie-
mens Healthcare Diagnostics). 
4. Comparison of results 
We analyzed essential agreement (EA) and categorical 
agreement (CA) between MICroSTREP and the CLSI refer-
ence method for each antibiotic tested. EA was defined as 
MIC of MICroSTREP and the CLSI reference method was 
within ±1 double dilution. CA was defined as interpretive 
category of MICroSTREP and the CLSI reference method 
was same. AST error rates were calculated and reported as 
follows: a very major error (VME) was recorded if an isolate 
was found to be susceptible on using MICroSTREP and re-
sistant on employing the reference method; a major error 
(ME) was recorded if an isolate was found to be resistant on 
using MICroSTREP and susceptible on employing the ref-
erence method; and a minor error (MIE) was recorded if an 
isolate was judged intermediate on using MICroSTREP or Kim SJ, et al.  •  MICroSTREP Panel for BHS and VGS 
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the reference method and susceptible or resistant on em-
ploying the other method. 
RESULTS
Using the agar dilution method, the VGS non-suscepti-
bility rates were 57.6% for ampicillin (MIC ≥0.5 mg/L), 
59.3% for penicillin (MIC ≥0.25 mg/L), 22.0% for cefotax-
ime (MIC ≥2 mg/L), 28.8% for meropenem (MIC >0.5 
mg/L), 39.0% for erythromycin (MIC ≥0.5 mg/L), 22.0% 
for clindamycin (MIC ≥0.5 mg/L), and 13.6% for levoflox-
acin (MIC ≥4 mg/L). All BHS isolates were susceptible to 
ampicillin, penicillin, cefotaxime, and meropenem. Among 
the BHS isolates, the non-susceptibility rates for erythromy-
cin, clindamycin, and levofloxacin were 28.0%, 37.3%, and 
6.7%, respectively (Table 1). 
The overall EAs and CAs determined for MICroSTREP 
and the CLSI reference method were 98.2% and 96.9%, re-
spectively (Tables 2 and 3). For the BHS isolates, the EAs for 
individual antimicrobial agents ranged from 94.7% (eryth-
romycin) to 100% (penicillin, cefotaxime, meropenem, and 
levofloxacin), while the EA for ampicillin, clindamycin, and 
vancomycin was 98.7%. The CA for erythromycin was 96. 
0%; for cefotaxime, meropenem, levofloxacin, and vanco-
mycin, 100%; and for ampicillin, penicillin, and clindamy-
cin, 98.7%. For the VGS isolates, the EAs ranged from 91. 
5% (penicillin) to 100% (cefotaxime, erythromycin, clinda-
mycin, and levofloxacin), and the EA for ampicillin and 
vancomycin was 96.6%. The CAs ranged from 84.7% (peni-
cillin) to 100% (erythromycin, clindamycin, and vancomy-
cin). The CAs for ampicillin and meropenem were 88.1% 
and 86.5%, respectively, and the CA for cefotaxime and le-
vofloxacin was 96.6%. 
Of the total 134 isolates, all categorical errors were MIEs 
(Table 3). In the cases of 14 isolates for which MIEs were 
obtained for penicillin and/or ampicillin, MIEs for penicil-
lin and ampicillin were obtained with 4 isolates (3 S. mitis 
isolates, 1 S. anginosus isolate); MIE only for penicillin was 
obtained with 6 isolates (4 S. mitis isolates, 1 S. anginosus 
Table 1. Results of MIC ranges and interpretive category obtained by using 





MIC (mg/L) results % of interpretive category
MIC range MIC50 MIC90 S I R
Ampicillin BHS 0.03-0.25 0.06 0.06 100
VGS 0.03-128 0.25 16 42.4     42.4     15.2
Penicillin BHS 0.03-0.12 0.03 0.06 100
VGS 0.03-128 0.12 16 40.7 39.0 20.3
Cefotaxime BHS 0.03-0.25 0.03 0.03 100
VGS 0.03-512 0.12 8 78.0 1.7 20.3
Meropenem BHS 0.03-0.25 0.03 0.03 100
VGS 0.03-64 0.12 4 71.2 -* -*
Erythromycin BHS 0.03-512 0.03 256 72.0 4.0 24.0
VGS 0.03-512 0.06 256 61.0 39.0
Clindamycin BHS 0.03-512 0.06 256 63.7 2.6 34.7
VGS 0.03-512 0.03 128 78.0 22.0
Levofloxacin BHS 0.25-32 0.5 0.5 93.3 6.7
VGS 0.25-32 0.5 2 86.4 13.6
Vancomycin BHS 0.12-1 0.5 0.5 100
VGS 0.12-1 0.25 0.5 100
*Any interpretive category other than susceptible was classified as a nonsusceptible 
category when meropenem was tested for VGS.
Abbreviations: MIC, minimal inhibitory concentration; S, susceptible; I, intermediate; 
R, resistant; BHS, β-hemolytic streptococci; VGS, viridans group streptococci.
Table 2. Comparison of MICs determined by using MICroSTREP with MICs 




N of MICs by MICroSTREP within indicated 
log2 of reference MICs % agreement
(±1 dilution)
-3 -2 -1 Same +1 +2 +3
Ampicillin BHS   3   64   7 1 98.7
VGS 2 10   39   8 96.6
Total  2 13 103 15 1 97.8
Penicillin BHS 25   43   7 100
VGS 5 27   26   1 91.5
Total  5 52   69   8 96.3
Cefotaxime BHS   75 100
VGS   8   48   3 100
Total    8 123   3 100
Meropenem  BHS   75 100
VGS 2 22   32   2 1 94.9
Total  2 22 107   2 1 100
Erythromycin BHS 3 16   55 1 94.7
VGS   9   50 100
Total  3 25 105 1 93.2
Clindamycin BHS 15   59 98.7
VGS   4   54   1 100
Total  19 113   1 99.3
Levofloxacin BHS 3   52 20 100
VGS 11   42   6 100
Total  14   94 26 100
Vancomycin BHS   3   64   7 1 98.7
VGS 2 10   39   8 96.6
Total  2 13 103 15 1 97.8
Abbreviations: MIC, minimal inhibitory concentration; MICroSTREP, MicroScan MICro-
STREP plus antimicrobial panel; BHS, β-hemolytic streptococci; VGS, viridans group 
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isolate, and 1 S. agalactiae isolate); and MIE only for ampi-
cillin was obtained with 4 isolates (2 S. mitis isolates, 1 S. 
anginosus isolate, 1 S. agalactiae isolate). The frequency of 
total MIEs obtained with BHS isolates was lower than that 
obtained with VGS isolates (Table 4). 
DISCUSSION
Healthcare professionals are faced with a variety of signifi-
cant, fastidious organisms, including S. pneumoniae, BHS, 
and VGS, that are increasingly showing resistance to com-
monly used antimicrobial agents. Although, in the past, 
many laboratories may have chosen to screen VGS isolated 
from normally sterile body sites, e.g. cerebrospinal fluid, 
blood, and bone, to determine penicillin resistance, the rapid 
spread of multidrug-resistant strains requires a more aggres-
sive approach. In addition, certain antimicrobials (penicillin, 
ampicillin, ertapenem, meropenem, and daptomycin) that 
may be used to treat VGS infections cannot be reliably tested 
using the disk diffusion method [9]. The CLSI also recom-
mends the inclusion of penicillin (or ampicillin), cefepime 
(cefotaxime or ceftriaxone), erythromycin, clindamycin, and 
vancomycin in a routine, primary testing panel [9]. 
The accuracy and efficiency of AST dictates timely and ap-
propriate decisions in choosing the antibiotic therapy. Auto-
mated systems with built-in expert systems can potentially 
increase the reproducibility and reliability of test results, and 
thus can be expected to improve the quality of patient care. 
In this study, penicillin-intermediate, and/or ampicillin-in-
termediate, and VGS isolates that were not susceptible to 
meropenem accounted for the bulk of the total MIEs. De-
spite the elevated frequency of MIEs obtained with VGS, the 
high EA values for penicillin, ampicillin, and meropenem 
suggest that these errors can be largely attributed to the 
MICs being close to the interpretive breakpoints (Table 4). 
In particular, all categorical errors for meropenem occurred 
when the MICroSTREP MIC was 2-fold dilution lower than 
the reference. The overall frequency of MIEs obtained with 
BHS was lower than that obtained with VGS, but MIEs for 
erythromycin and clindamycin were only detected with 
BHS. The highest MIE rates obtained for penicillin were 
similar to those reported by Guthrie et al. [12], who reported 
that penicillin was responsible for the highest MIE rate ob-
tained with S. pneumoniae. When the reference MIC was 
close to a breakpoint value, 2 MIEs were observed for several 
isolates [13]. For most antibiotics, the MICroSTREP MICs 
tended to be lower than the reference MICs, which greatly 
contributed to the number of MIEs. The exceptions were the 
MIC results for ampicillin, levofloxacin, and vancomycin 
obtained with BHS: MICroSTREP reported higher MICs in 
these cases (Table 2). No VMEs or MEs were detected, and 
relatively few MIEs were observed. The only observed excep-
tions to the performance standards were categorical dis-
agreement in cases of ampicillin, penicillin, and meropenem 
for VGS. The more the isolate population was concentrated 
near the MIC breakpoint level, the greater the possibility of 
categorical discrepancies between the results obtained using 
the testing instrument and the reference method. In con-
trast, the more the isolate population was distributed far 
away from MIC breakpoint level, the lesser the possibility of 
categorical discrepancies. Although diagnostic performance 
of the MIC testing system in BHS and VGS has not been re-
ported, Jorgensen et al. [14] reported that MICroSTREP did 
not result in any VMEs or MEs and that high EA and CA 
Table 3. Interpretive category errors determined by comparing MICroSTREP 
and reference MICs for 134 BHS (75) and VGS (59) isolates
Antimicrobial
agents Organisms
N (%) interpretive category discrepancies
Complete agreement Minor error
Ampicillin BHS 74 (98.7) 1 (1.3)
  VGS 52 (88.1) 7 (11.9)
Total  126 (94.0) 8 (6.0)
Penicillin BHS 74 (98.7) 1 (1.3)
  VGS 50 (84.7) 9 (15.3)
Total  124 (92.5) 10 (7.5)
Cefotaxime BHS 75 (100)           
  VGS 57 (96.6) 2 (3.4)
Total  132 (98.5) 2 (1.5)
Meropenem BHS 75 (100)            
  VGS 51 (86.5)            
Total  126 (94.0) -* 
Erythromycin BHS 72 (96.0) 3 (4.0)
  VGS 59 (100)           
Total  131 (92.4) 3 (2.2)
Clindamycin BHS 74 (98.7) 1 (1.3)
  VGS 59 (100)            
Total  133 (99.3) 1 (0.7)
Levofloxacin BHS 75 (100)            
  VGS 57 (96.6) 2 (3.4)
Total  133 (99.3) 1 (0.7)
Vancomycin BHS 75 (100)
  VGS 57 (100)
Total  134 (100)
*Minor errors were not evaluated because any interpretive characteristic other than 
susceptibility was classified nonsusceptibility when meropenem was tested for VGS.
Abbreviations: MICroSTREP, MicroScan MICroSTREP plus antimicrobial panel; MIC, 
minimal inhibitory concentration; BHS, β-hemolytic streptococci; VGS, viridans group 
streptococci.Kim SJ, et al.  •  MICroSTREP Panel for BHS and VGS 
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values were achieved in testing with S. pneumoniae. The 
high EA and CA values obtained by using MICroSTREP 
satisfied the minimal performance criteria (CA, ≥90%; EA, 
≥90%; VMEs, ≤1.5%; and MEs, ≤3%) of the Food and 
Drug Administration (FDA) [15]. The FDA suggested that 
50% susceptible and 50% resistant distribution is desired to 
generate meaningful statistics regarding the performance 
characteristics of a method or system [15]. However, it was 
unlikely that sequentially collected isolates from clinical 
samples would be anything similar to the 50% susceptible 
and 50% resistant distribution suggested by the FDA. 
The performance of MICroSTREP affirms the capability 
of the instrument as a reliable and efficient diagnostic tool 
for determining the appropriate antimicrobial agents for use 
Table 4. Difference (log2 dilution) in MICs determined using MICroSTREP and reference method for 27 isolates showing categorical error by interpretive criteria
Organisms
MIC difference (log2 dilution) according to antimicrobial agents
Penicillin Ampicillin Cefotaxime Meropenem Erythromycin Clindamycin Levofloxacin
S. pyogenes -2 (SI*) -3 (SI)
S. agalactiae +1 (IS
†)
S. agalactiae +2 (IS)
S. dysgalactiae -2 (SI)
S. dysgalactiae -2 (SI)
S. mitis -1 (SI) -1 (SI)
S. mitis -1 (SI) -1 (SI)
S. mitis -1 (SI) +1 (IS)
S. mitis -2 (SI) -1 (IR
‡)
S. mitis -2 (IR)
S. mitis -1 (SI)
S. mitis +1 (IS)
S. mitis -1 (SI)
S. mitis -1 (SI) -1 (SNS
§)
S. mitis -1 (SNS)
S. mitis -1 (SNS)
S. mitis -1 (SNS)
S. mitis -1 (SNS)
S. mitis -1 (SNS)
S. mitis
S. mitis -1 (SI)
S. mitis -1 (SI)
S. anginosus -1 (SI) +1 (IS)
S. anginosus -2 (SI) -1 (SNS)
S. anginosus
S. sanguinis -1 (SI) -1 (SNS)
S. sanguinis -1 (SI)
*judged susceptible using MICroSTREP and intermediate using the reference method; 
†judged intermediate using MICroSTREP and susceptible using the reference method; 
‡judged 
intermediate using MICroSTREP and resistant using the reference method; 
§judged susceptible using MICroSTREP and non-susceptible using the reference method.
Abbreviations: MIC, minimal inhibitory concentration; MICroSTREP, MicroScan MICroSTREP plus antimicrobial panel; BHS, β-hemolytic streptococci; VGS, viridans group streptococci.
against VGS and BHS infections. In conclusion, this instru-
ment was able to decrease the turnaround time to results 
because of the reduced hands-on time required in compari-
son to that required in conventional laboratory methods. 
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